SG11201707525TA - Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency - Google Patents
Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiencyInfo
- Publication number
- SG11201707525TA SG11201707525TA SG11201707525TA SG11201707525TA SG11201707525TA SG 11201707525T A SG11201707525T A SG 11201707525TA SG 11201707525T A SG11201707525T A SG 11201707525TA SG 11201707525T A SG11201707525T A SG 11201707525TA SG 11201707525T A SG11201707525T A SG 11201707525TA
- Authority
- SG
- Singapore
- Prior art keywords
- glucocorticoids
- combination
- receptor antagonists
- glucocorticoid receptor
- adrenal insufficiency
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140317P | 2015-03-30 | 2015-03-30 | |
| PCT/US2016/024981 WO2016160969A1 (en) | 2015-03-30 | 2016-03-30 | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707525TA true SG11201707525TA (en) | 2017-10-30 |
Family
ID=57006281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707525TA SG11201707525TA (en) | 2015-03-30 | 2016-03-30 | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10610534B2 (en) |
| EP (1) | EP3277281B1 (en) |
| JP (3) | JP6754533B2 (en) |
| KR (1) | KR102495223B1 (en) |
| CN (1) | CN107530339B (en) |
| AU (1) | AU2016243625B2 (en) |
| CA (1) | CA2978960C (en) |
| ES (1) | ES2906778T3 (en) |
| HK (1) | HK1248126A1 (en) |
| IL (1) | IL254787B (en) |
| MX (1) | MX2017011885A (en) |
| SG (1) | SG11201707525TA (en) |
| WO (1) | WO2016160969A1 (en) |
| ZA (1) | ZA201706101B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016160969A1 (en) | 2015-03-30 | 2016-10-06 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
| US10941473B2 (en) | 2015-09-03 | 2021-03-09 | Questek Innovations Llc | Aluminum alloys |
| GB201816621D0 (en) * | 2018-10-12 | 2018-11-28 | Univ Leuven Kath | Prevention or treatment of adrenal insuffiency in critically ill patients |
| JP2023065127A (en) | 2021-10-27 | 2023-05-12 | キヤノン株式会社 | Ink and image reading method |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4296206A (en) | 1980-04-30 | 1981-10-20 | United States Of America | Irreversible anti-glucocorticoids |
| ZA8231B (en) | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
| US4978657A (en) | 1981-01-09 | 1990-12-18 | Roussel Uclaf | Novel 11β-substituted-19-nor-steroids |
| FR2528434B1 (en) | 1982-06-11 | 1985-07-19 | Roussel Uclaf | NOVEL 19-NOR STEROIDS SUBSTITUTED IN 11B AND POSSIBLY IN 2, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS A MEDICAMENT |
| FR2639045B2 (en) | 1982-03-01 | 1994-07-29 | Roussel Uclaf | NEW PRODUCTS DERIVED FROM THE STRUCTURE 3-CETO-DELTA-4,9-19-NOR STEROIDS AND THEIR APPLICATION AS MEDICAMENTS |
| FR2522328B1 (en) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | NEW PRODUCTS DERIVED FROM THE STRUCTURE 3-CETO 4,9 19-NOR STEROIDS, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
| DE3438994A1 (en) | 1984-10-22 | 1986-04-24 | Schering AG, Berlin und Bergkamen, 1000 Berlin | ANTIGESTAGENE, GLUCOCORTICOIDS AND PROSTAGLANDINE FOR THE INTRODUCTION OF BIRTH OR FOR THE ABORT OF PREGNANCY |
| FR2576025B1 (en) | 1985-01-14 | 1987-01-23 | Roussel Uclaf | NOVEL SUBSTITUTED STEROIDS IN POSITION 10, THEIR PROCESS AND THE PREPARATION INTERMEDIATES, THEIR APPLICATION AS MEDICAMENTS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| NZ214998A (en) | 1985-02-07 | 1989-06-28 | Schering Ag | 13-(methyl or ethyl)-11-beta-phenyl-gonane derivatives; preparatory processes and pharmaceutical compositions |
| DE3506785A1 (en) | 1985-02-22 | 1986-08-28 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 11SS-N, N-DIMETHYLAMINOPHENYL ESTRADIENE, THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
| US5506354A (en) | 1985-09-12 | 1996-04-09 | The Upjohn Company | Imidazolylpiperazinyl steroids |
| FR2598421B1 (en) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | NOVEL 19-NOR OR 19-NOR D-HOMO STEROIDS SUBSTITUTED IN POSITION 11B BY A RADICAL PHENYL CARRYING AN ALKYNYL RADICAL, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM |
| DE3761308D1 (en) | 1986-07-23 | 1990-02-08 | Akzo Nv | 18-PHENYLESTRANE DERIVATIVES. |
| DE3625315A1 (en) | 1986-07-25 | 1988-01-28 | Schering Ag | 11SS- (4-ISOPROPENYLPHENYL) -ESTRA-4,9-DIENES, THEIR PRODUCTION AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
| US4774236A (en) | 1986-09-17 | 1988-09-27 | Research Triangle Institute | 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them |
| US4861763A (en) | 1986-09-17 | 1989-08-29 | Research Triangle Institute | 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use |
| US4921638A (en) | 1986-11-05 | 1990-05-01 | The Upjohn Company | 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one |
| DE3708942A1 (en) | 1987-03-18 | 1988-09-29 | Schering Ag | 19.11SS-BRIDGED STEROIDS, THEIR PRODUCTION AND THEIR PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
| DE3723788A1 (en) | 1987-07-16 | 1989-01-26 | Schering Ag | 11 (BETA) -PHENYL-4,9,15-ESTRATRIENE, THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
| FR2618783B1 (en) | 1987-07-30 | 1991-02-01 | Roussel Uclaf | NOVEL 17-ARYL STEROIDS, THEIR PROCESSES AND INTERMEDIATES AS A MEDICAMENT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| BE1004905A4 (en) | 1987-12-30 | 1993-02-23 | Roussel Uclaf | NOVEL 17BETA-OH 19-NOR DERIVATIVES SUBSTITUTED IN 17ALPHA, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| DE3820948A1 (en) | 1988-06-16 | 1989-12-21 | Schering Ag | 10SS, 11SS BRIDGED STEROIDS |
| US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| US5348729A (en) | 1988-11-30 | 1994-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Evaluative means for detecting inflammatory reactivity |
| DD289541A5 (en) | 1989-08-04 | 1991-05-02 | ��@�K@�������������@�K@��������������@��������k�� | PROCESS FOR THE PREPARATION OF 11BETA-ARYL-16 ALPHA, 17 ALPH-CYCLOHEXANOESTRA-4,9-DIENES |
| US5276023A (en) | 1989-08-08 | 1994-01-04 | Roussel Uclaf | 19-nor-steroid esters |
| FR2651233B1 (en) | 1989-08-23 | 1991-12-13 | Roussel Uclaf | NOVEL OMEGA-PHENYLAMINO ALKANOUIC ACIDS SUBSTITUTED ON THE AROMATIC CORE BY A RADICAL DERIVATIVE OF 19-NORSTEROUIDES, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM. |
| US5173405A (en) | 1990-01-23 | 1992-12-22 | The United States Of America As Represented By The Department Of Health And Human Services | Use of arsenite to reversibly block steroid binding to glucocorticoid receptors in the presence of other steroid receptors |
| US5616458A (en) | 1990-03-14 | 1997-04-01 | Board Of Regents, University Of Tx System | Tripterygium wilfordii hook F extracts and components, and uses thereof |
| DE4042004A1 (en) | 1990-12-22 | 1992-06-25 | Schering Ag | 14 (BETA) -H-, 14- & 15-EN-11 (BETA) -ARYL-4-ESTRENE |
| US5439913A (en) | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
| CA2149496C (en) | 1994-05-19 | 2006-12-19 | Ronald Gebhard | 11,21-bisphenyl-19-norpregnane derivatives |
| US6051573A (en) | 1994-06-28 | 2000-04-18 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists |
| US5688808A (en) | 1994-12-22 | 1997-11-18 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| NZ300739A (en) | 1994-12-22 | 2000-05-26 | Ligand Pharm Inc | Steroid receptor modulator compounds |
| IL118974A (en) | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | 11-(substituted phenyl)-estra-4,9-diene derivatives, their preparation and pharmaceutical compositions containing them |
| AU5729098A (en) | 1996-12-24 | 1998-07-17 | Zymogenetics Inc. | Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes |
| EP0903146A1 (en) | 1997-09-23 | 1999-03-24 | Applied Research Systems ARS Holdings N.V. | 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid |
| DE10038639A1 (en) | 2000-07-28 | 2002-02-21 | Schering Ag | New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism |
| IL146057A (en) | 2000-10-27 | 2007-09-20 | Pfizer Prod Inc | Process for the preparation of non-steroidal glucocorticoid receptor modulators |
| GB0119848D0 (en) | 2001-08-15 | 2001-10-10 | Univ Sheffield | Delayed and sustained drug release |
| EP1453495A2 (en) | 2001-11-23 | 2004-09-08 | Akzo Nobel N.V. | Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists |
| CA2512987C (en) * | 2003-01-21 | 2011-06-14 | Merck & Co., Inc. | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
| CN1742007A (en) | 2003-01-22 | 2006-03-01 | 伊莱利利公司 | Indole-derivative modulators of steroid hormone nuclear receptors |
| EP1735308B1 (en) | 2004-03-09 | 2008-09-10 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| SE0401031D0 (en) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| US20100261693A1 (en) * | 2007-10-17 | 2010-10-14 | Ulmann Andre | Method for treating cushing's syndrome |
| WO2010132445A1 (en) | 2009-05-12 | 2010-11-18 | Corcept Therapeutics, Inc. | Solid forms and process for preparing |
| JP2014501785A (en) * | 2011-01-07 | 2014-01-23 | コーセプト セラピューティクス， インコーポレイテッド | Steroid and glucocorticoid receptor antagonist combination therapy |
| SG193509A1 (en) | 2011-03-18 | 2013-10-30 | Corcept Therapeutics Inc | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
| PT3338781T (en) * | 2012-05-25 | 2019-11-29 | Corcept Therapeutics Inc | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US20140170768A1 (en) * | 2012-12-14 | 2014-06-19 | Joel R. L. Ehrenkranz | Method for monitoring and assessing pituitary function |
| PL3560493T3 (en) | 2013-11-25 | 2021-10-04 | Corcept Therapeutics Incorporated | Octahydro fused azadecalin glucocorticoid receptor modulators |
| WO2016160969A1 (en) | 2015-03-30 | 2016-10-06 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
-
2016
- 2016-03-30 WO PCT/US2016/024981 patent/WO2016160969A1/en active Application Filing
- 2016-03-30 JP JP2017550837A patent/JP6754533B2/en not_active Expired - Fee Related
- 2016-03-30 EP EP16774094.3A patent/EP3277281B1/en active Active
- 2016-03-30 US US15/565,291 patent/US10610534B2/en active Active
- 2016-03-30 MX MX2017011885A patent/MX2017011885A/en unknown
- 2016-03-30 CN CN201680018628.1A patent/CN107530339B/en not_active Expired - Fee Related
- 2016-03-30 SG SG11201707525TA patent/SG11201707525TA/en unknown
- 2016-03-30 KR KR1020177031245A patent/KR102495223B1/en active IP Right Grant
- 2016-03-30 ES ES16774094T patent/ES2906778T3/en active Active
- 2016-03-30 CA CA2978960A patent/CA2978960C/en active Active
- 2016-03-30 AU AU2016243625A patent/AU2016243625B2/en active Active
-
2017
- 2017-09-07 ZA ZA2017/06101A patent/ZA201706101B/en unknown
- 2017-09-28 IL IL254787A patent/IL254787B/en active IP Right Grant
-
2018
- 2018-06-14 HK HK18107709.7A patent/HK1248126A1/en unknown
-
2020
- 2020-02-06 JP JP2020018526A patent/JP2020073588A/en not_active Withdrawn
- 2020-03-11 US US16/816,014 patent/US11202784B2/en active Active
-
2021
- 2021-08-10 JP JP2021130694A patent/JP2021175756A/en active Pending
- 2021-11-12 US US17/525,409 patent/US11890289B2/en active Active
-
2023
- 2023-12-22 US US18/394,672 patent/US20240156835A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016160969A1 (en) | 2016-10-06 |
| CN107530339B (en) | 2021-03-16 |
| EP3277281A1 (en) | 2018-02-07 |
| US10610534B2 (en) | 2020-04-07 |
| US11890289B2 (en) | 2024-02-06 |
| HK1248126A1 (en) | 2018-10-12 |
| CA2978960C (en) | 2023-05-02 |
| JP2018510174A (en) | 2018-04-12 |
| JP2021175756A (en) | 2021-11-04 |
| MX2017011885A (en) | 2018-02-19 |
| CA2978960A1 (en) | 2016-10-06 |
| US11202784B2 (en) | 2021-12-21 |
| AU2016243625B2 (en) | 2020-09-10 |
| US20180078565A1 (en) | 2018-03-22 |
| ZA201706101B (en) | 2020-03-25 |
| AU2016243625A1 (en) | 2017-09-28 |
| CN107530339A (en) | 2018-01-02 |
| IL254787B (en) | 2020-05-31 |
| EP3277281A4 (en) | 2018-12-05 |
| KR102495223B1 (en) | 2023-02-01 |
| IL254787A0 (en) | 2017-12-31 |
| KR20170131665A (en) | 2017-11-29 |
| EP3277281B1 (en) | 2022-01-05 |
| JP6754533B2 (en) | 2020-09-16 |
| JP2020073588A (en) | 2020-05-14 |
| US20200206243A1 (en) | 2020-07-02 |
| ES2906778T3 (en) | 2022-04-20 |
| US20240156835A1 (en) | 2024-05-16 |
| US20220062297A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200048I1 (en) | Fcrn antagonists and methods of use | |
| IL261502A (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
| HK1248126A1 (en) | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency | |
| IL284005A (en) | Inhibitors of glucocorticoid receptor | |
| HK1248128A1 (en) | Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors | |
| ZA201706671B (en) | Process for the preparation of androgen receptor antagonists and intermediates thereof | |
| PL2999475T3 (en) | Imidazolyl progesterone antagonists | |
| ZA201702813B (en) | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | |
| IL246320A0 (en) | Apparatuses and methods for fastening roofing strapsand structural members to roofs | |
| HRP20190141T1 (en) | Progesterone receptor antagonist dosage form | |
| EP3126378A4 (en) | Cardiotonic steroid antagonists and related methods | |
| GB201419269D0 (en) | Adrenal support and modalities that maintain the functional activity of the glucocorticoid receptor and induce autophargy: therapy for inflammatory stress | |
| TH1501006213A (en) | Dosage form of progesterone receptor antagonist |